Welcome to Sysmex Inostics
Empowering discoveries in oncology
We provide ultra-sensitive liquid biopsy solutions for exceptional ctDNA detection. We partner with BioPharma companies to aid cancer drug and diagnostic development to monitor therapy response, identify targetable resistance, and detect minimal residual disease (MRD).
Approach
Our Products & Solutions
Sensitive and specific liquid biopsy
News & Events
The latest
Sysmex Inostics & QIAGEN Highlight Cancer Companion Diagnostics Alliance at ASCO 2022
Two poster presentations utilizing Sysmex Inostics technology to be featured Baltimore, MD, June 2, 2022…
Sysmex Inostics Expands Blood Test Offerings for Detection of Acute Myeloid Leukemia
Joins Foundation for the National Institutes of Health Biomarkers Consortium Baltimore, MD, May 24, 2022…
Sysmex Inostics Introduces CLIA-Validated Highly Sensitive HNSCC-SEQ Testing Services for Head and Neck Cancer at the 2022 Molecular Medicine Tri-Conference
Presenting Poster of Clinical Trial Findings at 2022 Multidisciplinary Head and Neck Cancers Symposium Baltimore,…